BioPharma Resources

Drug Trial Radar · NCT01524341

Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

Last checked: Nov 19, 2026Latest source record: May 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Jan 2012

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 1, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAE609 at 30 mg/day

Conditions

  • Malaria

Interventions

  • KAE609Drug

    KAE609 was supplied as capsules for oral use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parasite clearance timeTime frame: From baseline to the time point when the blood parasite count is zero(up to a maximum of 5 days)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Bangkok, Thailand

  • Novartis Investigative Site

    Tak, Thailand

  • Novartis Investigative Site

    Tak Province, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.